Bradley Canino

Stifel | Healthcare

Bradley Canino is an analyst from Stifel specializing in the Healthcare sector. They are beginning to establish their track record, with 2 stock ratings so far. Their current stats show a success rate of 100.00% and an average return of 106.82%.

Bradley Canino has only issued 2 ratings so far. While the sample size is small, their early calls show a success rate of 100.00% and an average return of 106.82%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#49

Out of 4773

2

Total Ratings

+100.00%

Success Rate

+106.82%

Average Return

Recent Ratings Analysis

PYXS

Mar 24, 2026

Target

$8.00

Current

$3.21

Performance

136.03%

Bradley Canino rated PYXS as Buy on Mar 24, 2026, setting a price target of 8. The call has proven timely, with shares rising 136.03% toward the price target of 8.

JANX

Dec 02, 2025

Target

$46.00

Current

$17.10

Performance

7.82%

On Dec 02, 2025, JANX was given a Buy rating by Bradley Canino, with a target price of 46. The stock rallied 7.82% after the rating, narrowing the gap to the target of 46 and validating the bullish stance.

SNDX

Sep 10, 2025

Target

$44.00

Current

$18.18

Performance

15.58%

SNDX received a Buy rating from Bradley Canino on Sep 10, 2025, aiming for 44. Momentum has favored the Buy call, with shares climbing from 18.18 to 18.18, rewarding those who trusted the recommendation.

ALXO

Mar 07, 2025

Target

$1.50

Current

$1.94

Performance

83.02%

On Mar 07, 2025, Bradley Canino published a Hold outlook on ALXO, with a target of 1.5. The Hold call missed some of the bullish momentum as shares advanced toward 1.5.

BDTX

Mar 07, 2025

Target

$15.00

Current

$1.98

Performance

5.32%

Bradley Canino on Mar 07, 2025 assigned BDTX a Buy rating, with a price target of 15. The Buy call aligned well with market performance, producing a gain of 5.32%.

RLAY

Feb 27, 2025

Target

$23.00

Current

$18.87

Performance

480.62%

On Feb 27, 2025, Bradley Canino reaffirmed RLAY with a Buy rating, targeting 23. The recommendation was supported by strong follow-through as the stock rose from 18.87 to 18.87.

ARVN

Feb 12, 2025

Target

$51.00

Current

$8.45

Performance

-52.92%

ARVN was rated Buy by Bradley Canino on Feb 12, 2025, with a price objective of 51. This case shows how bullish projections can fail, with the stock now below 8.45.

AFMD

Nov 15, 2024

Target

$4.00

Current

$0.18

Performance

-94.78%

On Nov 15, 2024, Bradley Canino initiated coverage on AFMD with a Hold rating and target of 4. The rating matched the stock’s inability to hold above 0.1815.

KURA

Oct 14, 2024

Target

$19.00

Current

$11.39

Performance

-36.93%

Bradley Canino issued a Hold recommendation for KURA on Oct 14, 2024, price target set at 19. Market action validated the conservative Hold outlook with shares at 11.39.

CELC

Oct 07, 2024

Target

$42.00

Current

$83.45

Performance

446.50%

On Oct 07, 2024, CELC was evaluated by Bradley Canino, who gave a Buy rating and target of 42. This case illustrates how a timely bullish rating can translate into tangible gains of 446.50%.

SMMT

Sep 25, 2024

Target

$40.00

Current

$17.55

Performance

-22.48%

Bradley Canino rated SMMT as Buy on Sep 25, 2024, setting a price target of 40. The stock has underperformed, dropping 22.48% despite the bullish target of 40.

NUVL

Sep 16, 2024

Target

$135.00

Current

$123.96

Performance

10.51%

On Sep 16, 2024, NUVL was given a Buy rating by Bradley Canino, with a target price of 135. The stock rallied 10.51% after the rating, narrowing the gap to the target of 135 and validating the bullish stance.

ZNTL

Jun 18, 2024

Target

$10.00

Current

$3.51

Performance

-15.22%

ZNTL received a Buy rating from Bradley Canino on Jun 18, 2024, aiming for 10. The rating hasn’t played out as hoped, with the stock trading 15.22% below expectations.

MRUS

Jun 17, 2024

Target

$99.00

Current

$90.00

Performance

61.38%

On Jun 17, 2024, Bradley Canino published a Buy outlook on MRUS, with a target of 99. Shares gained 61.38%, underscoring the accuracy of the bullish outlook toward 99.

CCCC

May 09, 2024

Target

$14.00

Current

$3.51

Performance

-48.38%

Bradley Canino on May 09, 2024 assigned CCCC a Buy rating, with a price target of 14. The call has struggled to gain traction, with shares losing 48.38%.

CGEM

May 01, 2024

Target

$40.00

Current

$20.59

Performance

-26.73%

On May 01, 2024, Bradley Canino reaffirmed CGEM with a Buy rating, targeting 40. Shares slid 26.73% despite the recommendation, highlighting downside risks.

BPMC

Apr 26, 2024

Target

$130.00

Current

$129.46

Performance

39.20%

BPMC was rated Buy by Bradley Canino on Apr 26, 2024, with a price objective of 130. A bullish response from the market helped close the gap of 0.54 to the target.

DCPH

Feb 07, 2024

Target

$23.00

Current

$25.59

Performance

82.52%

On Feb 07, 2024, Bradley Canino initiated coverage on DCPH with a Buy rating and target of 23. The stock’s climb of 82.52% since the call highlights the foresight in the rating.

Frequency Asked Questions

Who is Bradley Canino?

Bradley Canino is an analyst from Stifel specializing in the Healthcare sector.

What is Bradley Canino's success rate?

Bradley Canino currently has a success rate of +100.00%.

How many ratings has Bradley Canino issued?

Bradley Canino has issued 2 stock ratings so far.

What is the average return of Bradley Canino's calls?

Their stock ratings have generated an average return of +106.82%.

What is Bradley Canino's ranking?

Bradley Canino is ranked #49 out of 4773 analysts.

What types of ratings does Bradley Canino give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Bradley Canino?

You can follow Bradley Canino by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Bradley Canino?

Their latest rating was a Buy on PYXS issued on 2026-03-24.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep